Penile metastasis from colon cancer with BRAFV600E mutation treated with BRAF/MEK-targeted therapy plus cetuximab: A case report

doi:10.4251/wjgo.v17.i3.100152

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

(111)

(122)

(0)

(1)

(2581)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Mar 15, 2025; 17(3): 100152
Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.100152

Full Size Figure Download Figure

Figure 1 Computed tomography scans of the patient upon admission: The diseased segment exhibited thickening of the intestinal wall, rough surface texture, and significantly increased enhancement on the enhanced scan. The proximal colon was obstructive dilatation.

Citation: Wu JC, Cheng HX, Lan QS, Xu HY, Zeng YJ, Lai W, Chu ZH. Penile metastasis from colon cancer with BRAF^V600E mutation treated with BRAF/MEK-targeted therapy plus cetuximab: A case report. World J Gastrointest Oncol 2025; 17(3): 100152
URL: https://www.wjgnet.com/1948-5204/full/v17/i3/100152.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i3.100152

Wu JC, Cheng HX, Lan QS, Xu HY, Zeng YJ, Lai W, Chu ZH. Penile metastasis from colon cancer with BRAF^V600E mutation treated with BRAF/MEK-targeted therapy plus cetuximab: A case report. World J Gastrointest Oncol 2025; 17(3): 100152 [PMID: 40092928 DOI: 10.4251/wjgo.v17.i3.100152]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.